Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.

AB-680 is a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity.

Pulsatilla saponin D has exhibited potential beneficial effects as a chemopreventive agent for critical health conditions including cancer and it inhibits cell growth via cell cycle arrest and apoptosis in various cancer cell types.